{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:24:14Z","timestamp":1792416254975,"version":"4.4.0"},"reference-count":111,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>The treatment of relapsed\/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies. Selecting treatment options for relapsed\/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed\/refractory disease.<\/jats:p>","DOI":"10.6004\/jnccn.2023.0061","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T15:47:56Z","timestamp":1702309676000},"page":"1281-1301","source":"Crossref","is-referenced-by-count":156,"title":["Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"21","author":[{"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Adekola","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Campagnaro","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Devarakonda","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Elsedawy","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Garfall","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Godby","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larson","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Omel","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Robinson","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sherbenou","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya Nina","family":"Varshavsky-Yanovsky","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Snedeker","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Cancer stat facts: myeloma","unstructured":"SEER. Cancer stat facts: myeloma. Accessed October 25, 2024. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS,  Cancer statistics, 2023. CA Cancer J Clin 2023;73:17\u201348."},{"key":"B3","series-title":"Blood","first-page":"421","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari A","year":"2019","unstructured":"Chari A, Martinez-Lopez J, Mateos MV,  Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2019;134:421\u2013431."},{"key":"B4","series-title":"Lancet","first-page":"186","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos M","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV,  Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;396:186\u2013197."},{"key":"B5","series-title":"Lancet Oncol","first-page":"65","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani SZ","year":"2022","unstructured":"Usmani SZ, Quach H, Mateos MV,  Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 2022;23:65\u201376."},{"key":"B6","series-title":"Lancet","first-page":"2361","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau P","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J,  Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021;397:2361\u20132371."},{"key":"B7","series-title":"HemaSphere","first-page":"e786","article-title":"Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma","volume":"6","author":"Sonneveld P","year":"2022","unstructured":"Sonneveld P, Zweegman S, Cavo M,  Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma. HemaSphere 2022;6:e786."},{"key":"B8","series-title":"Blood","first-page":"974","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari A","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW,  Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood 2017;130:974\u2013981."},{"key":"B9","series-title":"Lancet Oncol","first-page":"801","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M,  Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:801\u2013812."},{"key":"B10","series-title":"Leukemia","first-page":"3286","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel DS","year":"2020","unstructured":"Siegel DS, Schiller GJ, Samaras C,  Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia 2020;34:3286\u20133297."},{"key":"B11","series-title":"Lancet","first-page":"2096","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal M","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV,  Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394:2096\u20132107."},{"key":"B12","series-title":"Leukemia","first-page":"562","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis","volume":"35","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Leleu X, Moreau P,  Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia 2021;35:562\u2013572."},{"key":"B13","series-title":"Am J Hematol","first-page":"1595","article-title":"A phase I\/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)","volume":"96","author":"Voorhees PM","year":"2021","unstructured":"Voorhees PM, Suman VJ, Tuchman SA,  A phase I\/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol 2021;96:1595\u20131603."},{"key":"B14","series-title":"J Clin Oncol","article-title":"A phase I\/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R\/R) multiple myeloma: initial results","volume":"34","author":"Krishnan AY","year":"2016","unstructured":"Krishnan AY, Kapoor P, Palmer J,  A phase I\/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R\/R) multiple myeloma: initial results. J Clin Oncol 2016;34 (Suppl):Abstract 8008."},{"key":"B15","series-title":"N Engl J Med","first-page":"1319","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos MA","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H,  Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319\u20131331."},{"key":"B16","series-title":"Leukemia","first-page":"1875","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis NJ","year":"2020","unstructured":"Bahlis NJ, Dimopoulos MA, White DJ,  Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020;34:1875\u20131884."},{"key":"B17","series-title":"N Engl J Med","first-page":"142","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart AK","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA,  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142\u2013152."},{"key":"B18","series-title":"N Engl J Med","first-page":"754","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo A","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K,  Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754\u2013766."},{"key":"B19","series-title":"N Engl J Med","first-page":"1207","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst HM","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP,  Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207\u20131219."},{"key":"B20","series-title":"Lancet","first-page":"1551","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial S","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ,  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551\u20131560."},{"key":"B21","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"509","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos MV","year":"2020","unstructured":"Mateos MV, Sonneveld P, Hungria V,  Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 2020;20:509\u2013518."},{"key":"B22","series-title":"Lancet Oncol","first-page":"781","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson PG","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M,  Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:781\u2013794."},{"key":"B23","series-title":"Leukemia","first-page":"1722","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos M","year":"2021","unstructured":"Dimopoulos M, Weisel K, Moreau P,  Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia 2021;35:1722\u20131731."},{"key":"B24","series-title":"Lancet","first-page":"1563","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki S","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I,  Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020;396:1563\u20131573."},{"key":"B25","series-title":"N Engl J Med","first-page":"1811","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos MA","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S,  Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:1811\u20131822."},{"key":"B26","series-title":"J Clin Oncol","first-page":"568","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S,  Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol 2023;41:568\u2013578."},{"key":"B27","series-title":"Lancet Oncol","first-page":"27","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos MA","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A,  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016;17:27\u201338."},{"key":"B28","series-title":"Lancet Oncol","first-page":"1327","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos MA","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R,  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:1327\u20131337."},{"key":"B29","series-title":"N Engl J Med","first-page":"621","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial S","year":"2015","unstructured":"Lonial S, Dimopoulos MA, Palumbo A,  Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373:621\u2013631."},{"key":"B30","series-title":"Br J Haematol","first-page":"896","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"Dimopoulos MA","year":"2017","unstructured":"Dimopoulos MA, Lonial S, White D,  Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 2017;178:896\u2013905."},{"key":"B31","series-title":"Blood Cancer J","first-page":"91","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos MA","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D,  Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 2020;10:91."},{"key":"B32","series-title":"Lancet Oncol","first-page":"1503","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar SK","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R,  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol 2014;15:1503\u20131512."},{"key":"B33","series-title":"N Engl J Med","first-page":"1621","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau P","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N,  Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374:1621\u20131634."},{"key":"B34","series-title":"Haematologica","first-page":"1149","article-title":"The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone","volume":"92","author":"Davies FE","year":"2007","unstructured":"Davies FE, Wu P, Jenner M,  The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92:1149\u20131150."},{"key":"B35","series-title":"Br J Haematol","first-page":"330","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff M","year":"2007","unstructured":"Kropff M, Bisping G, Schuck E,  Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330\u2013337."},{"key":"B36","series-title":"J Clin Oncol","first-page":"5713","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson PG","year":"2009","unstructured":"Richardson PG, Weller E, Jagannath S,  Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma. J Clin Oncol 2009;27:5713\u20135719."},{"key":"B37","series-title":"Blood","first-page":"1461","article-title":"A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson PG","year":"2014","unstructured":"Richardson PG, Xie W, Jagannath S,  A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma. Blood 2014;123:1461\u20131469."},{"key":"B38","series-title":"Haematologica","first-page":"2694","article-title":"Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK five)","volume":"106","author":"Yong KL","year":"2021","unstructured":"Yong KL, Hinsley S, Auner HW,  Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK five). Haematologica 2021;106:2694\u20132706."},{"key":"B39","series-title":"Haematologica","first-page":"2753","article-title":"Randomized phase II study of weekly carfilzomib 70 mg\/m2 and dexamethasone with or without cyclophosphamide in relapsed and\/or refractory multiple myeloma patients","volume":"108","author":"Puertas B","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sureda A,  Randomized phase II study of weekly carfilzomib 70 mg\/m2 and dexamethasone with or without cyclophosphamide in relapsed and\/or refractory multiple myeloma patients. Haematologica 2023;108:2753\u20132763."},{"key":"B40","series-title":"Br J Haematol","first-page":"492","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer H","year":"2019","unstructured":"Yimer H, Melear J, Faber E,  Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 2019;185:492\u2013502."},{"key":"B41","series-title":"Blood","first-page":"2833","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak A","year":"2016","unstructured":"Jakubowiak A, Offidani M, P\u00e9gourie B,  Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM. Blood 2016;127:2833\u20132840."},{"key":"B42","series-title":"Blood Cancer J","first-page":"70","article-title":"Phase 1\/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma","volume":"8","author":"Kumar SK","year":"2018","unstructured":"Kumar SK, Buadi FK, LaPlant B,  Phase 1\/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 2018;8:70."},{"key":"B43","series-title":"Eur J Cancer","first-page":"89","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Grosicki S, J\u0119drzejczak WW,  All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89\u201398."},{"key":"B44","series-title":"Br J Haematol","first-page":"536","article-title":"Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"184","author":"Kumar SK","year":"2019","unstructured":"Kumar SK, Grzasko N, Delimpasi S,  Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed\/refractory multiple myeloma. Br J Haematol 2019;184:536\u2013546."},{"key":"B45","series-title":"Br J Haematol","first-page":"268","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients","volume":"137","author":"Morgan GJ","year":"2007","unstructured":"Morgan GJ, Schey SA, Wu P,  Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137:268\u2013269."},{"key":"B46","series-title":"Blood","first-page":"2561","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz RC","year":"2016","unstructured":"Baz RC, Martin TG 3rd, Lin HY,  Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 2016;127:2561\u20132568."},{"key":"B47","series-title":"Blood","first-page":"1858","article-title":"Pomalidomide, cyclophosphamide and dexamethasone for relapsed\/refractory multiple myeloma: a retrospective single center experience","volume":"126","author":"Garderet L","year":"2015","unstructured":"Garderet L, Polge E, Gueye mS,  Pomalidomide, cyclophosphamide and dexamethasone for relapsed\/refractory multiple myeloma: a retrospective single center experience. Blood 2015;126:1858."},{"key":"B48","series-title":"J Clin Oncol","first-page":"3892","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski RZ","year":"2007","unstructured":"Orlowski RZ, Nagler A, Sonneveld P,  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892\u20133901."},{"key":"B49","series-title":"Br J Haematol","first-page":"169","article-title":"High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program","volume":"144","author":"Mikhael JR","year":"2009","unstructured":"Mikhael JR, Belch AR, Prince HM,  High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009;144:169\u2013175."},{"key":"B50","series-title":"Br J Haematol","first-page":"165","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath S","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J,  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165\u2013172."},{"key":"B51","series-title":"Haematologica","first-page":"929","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone","volume":"91","author":"Jagannath S","year":"2006","unstructured":"Jagannath S, Richardson PG, Barlogie B,  Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929\u2013934."},{"key":"B52","series-title":"N Engl J Med","first-page":"2123","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos MA","year":"2007","unstructured":"Dimopoulos MA, Spencer A, Attal M,  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123\u20132132."},{"key":"B53","series-title":"N Engl J Med","first-page":"2133","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber DM","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R,  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133\u20132142."},{"key":"B54","series-title":"Br J Haematol","first-page":"219","article-title":"Phase Ib\/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma","volume":"169","author":"Mikhael JR","year":"2015","unstructured":"Mikhael JR, Reeder CB, Libby EN,  Phase Ib\/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol 2015;169:219\u2013227."},{"key":"B55","series-title":"Lancet Oncol","first-page":"953","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau P","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR,  Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018;19:953\u2013964."},{"key":"B56","series-title":"Br J Cancer","first-page":"718","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto C","year":"2022","unstructured":"Gasparetto C, Schiller GJ, Tuchman SA,  Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Br J Cancer 2022;126:718\u2013725."},{"key":"B57","series-title":"Blood","first-page":"10050","article-title":"Once weekly selinexor, carfilzomib and dexamethasone (XKd) in triple class refractory multiple myeloma","volume":"140","author":"Schiller GJ","year":"2022","unstructured":"Schiller GJ, Tuchman SA, Callander N,  Once weekly selinexor, carfilzomib and dexamethasone (XKd) in triple class refractory multiple myeloma. Blood 2022;140(Suppl 1):10050\u201310053."},{"key":"B58","series-title":"Blood","first-page":"2401","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar S","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C,  Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 2017;130:2401\u20132409."},{"key":"B59","series-title":"Br J Haematol","first-page":"1136","article-title":"Real-world data on safety and efficacy of venetoclax-based regimens in relapsed\/refractory t(11;14) multiple myeloma","volume":"189","author":"Basali D","year":"2020","unstructured":"Basali D, Chakraborty R, Rybicki L,  Real-world data on safety and efficacy of venetoclax-based regimens in relapsed\/refractory t(11;14) multiple myeloma. Br J Haematol 2020;189:1136\u20131140."},{"key":"B60","series-title":"Am J Hematol","first-page":"418","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman JL","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH,  Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol 2021;96:418\u2013427."},{"key":"B61","series-title":"J Clin Oncol","first-page":"3602","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis NJ","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ,  Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol 2021;39:3602\u20133612."},{"key":"B62","series-title":"Blood","first-page":"303","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Costa LJ","year":"2018","unstructured":"Costa LJ, Stadtmauer EA, Morgan G,  Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood 2018;132(Suppl 1):303."},{"key":"B63","series-title":"J Med Case Reports","first-page":"54","article-title":"Venetoclax in combination with carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature","volume":"14","author":"Abuelgasim KA","year":"2020","unstructured":"Abuelgasim KA, Alherz N, Alhejazi A,  Venetoclax in combination with carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature. J Med Case Reports 2020;14:54."},{"key":"B64","series-title":"Blood","first-page":"3227","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"G\u00f6rg\u00fcn G","year":"2010","unstructured":"G\u00f6rg\u00fcn G, Calabrese E, Soydan E,  Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116:3227\u20133237."},{"key":"B65","series-title":"Lancet Oncol","first-page":"1055","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel JS","year":"2013","unstructured":"Miguel JS, Weisel K, Moreau P,  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:1055\u20131066."},{"key":"B66","series-title":"Blood","first-page":"80","article-title":"Safety and efficacy in the stratus (MM-010) trial, a single-arm phase 3b study evaluating pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma","volume":"124","author":"Dimopoulos MA","year":"2014","unstructured":"Dimopoulos MA, Palumbo A, Weisel K,  Safety and efficacy in the stratus (MM-010) trial, a single-arm phase 3b study evaluating pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. Blood 2014;124:80."},{"key":"B67","series-title":"Blood","first-page":"1968","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02","volume":"121","author":"Leleu X","year":"2013","unstructured":"Leleu X, Attal M, Arnulf B,  Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02. Blood 2013;121:1968\u20131975."},{"key":"B68","series-title":"Blood","first-page":"2970","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy MQ","year":"2011","unstructured":"Lacy MQ, Allred JB, Gertz MA,  Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970\u20132975."},{"key":"B69","series-title":"J Clin Oncol","article-title":"Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM)","volume":"39","author":"White D","year":"2021","unstructured":"White D, Chen C, Baljevic M,  Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). J Clin Oncol 2021;39(Suppl):Abstract 8018."},{"key":"B70","series-title":"Bone Marrow Transplant","first-page":"835","article-title":"DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma","volume":"28","author":"Lazzarino M","year":"2001","unstructured":"Lazzarino M, Corso A, Barbarano L,  DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001;28:835\u2013839."},{"key":"B71","series-title":"J BUON","first-page":"41","article-title":"Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients","volume":"12","author":"Dadacaridou M","year":"2007","unstructured":"Dadacaridou M, Papanicolaou X, Maltesas D,  Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 2007;12:41\u201344."},{"key":"B72","series-title":"Cancer","first-page":"3622","article-title":"A comparison of salvage infusional chemotherapy regimens for recurrent\/refractory multiple myeloma","volume":"121","author":"Griffin PT","year":"2015","unstructured":"Griffin PT, Ho VQ, Fulp W,  A comparison of salvage infusional chemotherapy regimens for recurrent\/refractory multiple myeloma. Cancer 2015;121:3622\u20133630."},{"key":"B73","series-title":"J Clin Oncol","first-page":"2732","article-title":"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma","volume":"21","author":"Lee CK","year":"2003","unstructured":"Lee CK, Barlogie B, Munshi N,  DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732\u20132739."},{"key":"B74","series-title":"Eur J Haematol","first-page":"432","article-title":"Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE","volume":"81","author":"Srikanth M","year":"2008","unstructured":"Srikanth M, Davies FE, Wu P,  Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 2008;81:432\u2013436."},{"key":"B75","series-title":"Blood","first-page":"5377","article-title":"VDTPACE as salvage therapy for heavily pretreated MM patients","volume":"122","author":"Buda G","year":"2013","unstructured":"Buda G, Orciuolo E, Galimberti S,  VDTPACE as salvage therapy for heavily pretreated MM patients. Blood 2013;122:5377."},{"key":"B76","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"e57","article-title":"Efficacy and safety of VTD-PACE regimen in relapsed or refractory multiple myeloma","volume":"17","author":"Andoh S","year":"2017","unstructured":"Andoh S, Togano T, Itoi S,  Efficacy and safety of VTD-PACE regimen in relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2017;17(Suppl):e57."},{"key":"B77","series-title":"Am J Hematol","first-page":"179","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman A","year":"2018","unstructured":"Lakshman A, Singh PP, Rajkumar SV,  Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma. Am J Hematol 2018;93:179\u2013186."},{"key":"B78","series-title":"Nat Med","first-page":"2259","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin AM","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B,  Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259\u20132267."},{"key":"B79","series-title":"N Engl J Med","first-page":"2232","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari A","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG,  Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387:2232\u20132244."},{"key":"B80","series-title":"N Engl J Med","first-page":"495","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW,  Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387:495\u2013505."},{"key":"B81","series-title":"N Engl J Med","first-page":"705","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N,  Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705\u2013716."},{"key":"B82","series-title":"Lancet","first-page":"314","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja JG","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ,  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 2021;398:314\u2013324."},{"key":"B83","series-title":"Blood","first-page":"549","article-title":"Updated results from CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin T","year":"2021","unstructured":"Martin T, Usmani SZ, Berdeja JG,  Updated results from CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma. Blood 2021;138(Suppl 1):549."},{"key":"B84","series-title":"Haematologica","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy","volume":"90","author":"Knop S","year":"2005","unstructured":"Knop S, Straka C, Haen M,  The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287\u20131288."},{"key":"B85","series-title":"Eur J Med Res","first-page":"13","article-title":"Bendamustine in patients with relapsed or refractory multiple myeloma","volume":"15","author":"Michael M","year":"2010","unstructured":"Michael M, Bruns I, B\u00f6lke E,  Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15:13\u201319."},{"key":"B86","series-title":"Cancer","first-page":"1456","article-title":"High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma","volume":"53","author":"Lenhard RE Jr","year":"1984","unstructured":"Lenhard RE Jr, Oken MM, Barnes JM,  High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 1984;53:1456\u20131460."},{"key":"B87","series-title":"Blood Cancer J","first-page":"e162","article-title":"Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study","volume":"3","author":"Offidani M","year":"2013","unstructured":"Offidani M, Corvatta L, Maracci L,  Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 2013;3:e162."},{"key":"B88","series-title":"Cancer","first-page":"3413","article-title":"Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: the EMN09 phase 1\/2 study of the European Myeloma Network","volume":"127","author":"Gay F","year":"2021","unstructured":"Gay F, G\u00fcnther A, Offidani M,  Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: the EMN09 phase 1\/2 study of the European Myeloma Network. Cancer 2021;127:3413\u20133421."},{"key":"B89","series-title":"Blood","first-page":"4608","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study","volume":"119","author":"Lentzsch S","year":"2012","unstructured":"Lentzsch S, O\u2019Sullivan A, Kennedy RC,  Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study. Blood 2012;119:4608\u20134613."},{"key":"B90","series-title":"Am J Hematol","first-page":"699","article-title":"Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents","volume":"86","author":"Rivell GL","year":"2011","unstructured":"Rivell GL, Brunson CY, Milligan L,  Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol 2011;86:699\u2013701."},{"key":"B91","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"279","article-title":"Hyperfractionated cyclophosphamide and dexamethasone alone or in combination with daratumumab and\/or carfilzomib for the treatment of relapsed or refractory multiple myeloma: a single-center retrospective analysis","volume":"23","author":"Shank BR","year":"2023","unstructured":"Shank BR, Primeaux B, Yeung EK,  Hyperfractionated cyclophosphamide and dexamethasone alone or in combination with daratumumab and\/or carfilzomib for the treatment of relapsed or refractory multiple myeloma: a single-center retrospective analysis. Clin Lymphoma Myeloma Leuk 2023;23:279\u2013290."},{"key":"B92","series-title":"N Engl J Med","first-page":"727","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari A","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M,  Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381:727\u2013738."},{"key":"B93","series-title":"Lancet Oncol","first-page":"207","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial S","year":"2020","unstructured":"Lonial S, Lee HC, Badros A,  Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21:207\u2013221."},{"key":"B94","series-title":"J Clin Oncol","first-page":"593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson JR","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L,  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593\u2013602."},{"key":"B95","series-title":"N Engl J Med","first-page":"488","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson JR","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L,  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488\u2013493."},{"key":"B96","series-title":"J Clin Oncol","first-page":"558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major P","year":"2001","unstructured":"Major P, Lortholary A, Hon J,  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558\u2013567."},{"key":"B97","series-title":"Br J Haematol","first-page":"620","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas K","year":"2006","unstructured":"Zervas K, Verrou E, Teleioudis Z,  Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620\u2013623."},{"key":"B98","series-title":"Lancet","first-page":"1989","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan GJ","year":"2010","unstructured":"Morgan GJ, Davies FE, Gregory WM,  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989\u20131999."},{"key":"B99","series-title":"Br J Haematol","first-page":"109","article-title":"Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results","volume":"166","author":"Jackson GH","year":"2014","unstructured":"Jackson GH, Morgan GJ, Davies FE,  Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Br J Haematol 2014;166:109\u2013117."},{"key":"B100","series-title":"Clin Cancer Res","first-page":"6030","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan GJ","year":"2013","unstructured":"Morgan GJ, Davies FE, Gregory WM,  Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 2013;19:6030\u20136038."},{"key":"B101","series-title":"Cochrane Database Syst Rev","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","volume":"5","author":"Mhaskar R","year":"2012","unstructured":"Mhaskar R, Redzepovic J, Wheatley K,  Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012;5:CD003188."},{"key":"B102","series-title":"JAMA","first-page":"48","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein AL","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL,  Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 2017;317:48\u201358."},{"key":"B103","series-title":"Lancet Oncol","first-page":"370","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje N","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W,  Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018;19:370\u2013381."},{"key":"B104","series-title":"Semin Oncol","first-page":"17","article-title":"Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program","volume":"28","author":"Major PP","year":"2001","unstructured":"Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol 2001;28(Suppl 6):17\u201324."},{"key":"B105","series-title":"Support Care Cancer","first-page":"539","article-title":"Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate","volume":"11","author":"Pecherstorfer M","year":"2003","unstructured":"Pecherstorfer M, Steinhauer EU, Rizzoli R,  Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 2003;11:539\u2013547."},{"key":"B106","series-title":"Adv Radiat Oncol","first-page":"112","article-title":"The safety profile of concurrent therapy for multiple myeloma in the modern era","volume":"4","author":"Resende Salgado L","year":"2018","unstructured":"Resende Salgado L, Wang S, Adler A,  The safety profile of concurrent therapy for multiple myeloma in the modern era. Adv Radiat Oncol 2018;4:112\u2013117."},{"key":"B107","series-title":"Cancers (Basel)","first-page":"2273","article-title":"RR Myelo POINT: a retrospective single-center study assessing the role of radiotherapy in the management of multiple myeloma and possible interactions with concurrent systemic treatment","volume":"14","author":"Guerini AE","year":"2022","unstructured":"Guerini AE, Tucci A, Alongi F,  RR Myelo POINT: a retrospective single-center study assessing the role of radiotherapy in the management of multiple myeloma and possible interactions with concurrent systemic treatment. Cancers (Basel) 2022;14:2273."},{"key":"B108","series-title":"Haematologica","first-page":"e355","article-title":"New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity","volume":"105","author":"Elhammali A","year":"2020","unstructured":"Elhammali A, Amini B, Ludmir EB,  New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 2020;105:e355\u2013357."},{"key":"B109","series-title":"Am J Med","first-page":"682","article-title":"Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein","volume":"54","author":"Lindsley H","year":"1973","unstructured":"Lindsley H, Teller D, Noonan B,  Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med 1973;54:682\u2013688."},{"key":"B110","series-title":"N Engl J Med","first-page":"1693","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig H","year":"1990","unstructured":"Ludwig H, Fritz E, Kotzmann H,  Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693\u20131699."},{"key":"B111","series-title":"Blood","first-page":"2675","article-title":"Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin\u2019s lymphoma\u2014a randomized multicenter study","volume":"87","author":"Osterborg A","year":"1996","unstructured":"Osterborg A, Boogaerts MA, Cimino R,  Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin\u2019s lymphoma\u2014a randomized multicenter study. Blood 1996;87:2675\u20132682."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/12\/article-p1281.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/12\/article-p1281.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/12\/article-p1281.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T15:51:17Z","timestamp":1702309877000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/12\/article-p1281.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":111,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.0061","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}